preloader

2767(E)

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary, dated the 27th November, 2008)

Government of India
Ministry of Chemicals and Fertilizers
(National Pharmaceuticals Pricing Authority)

                                                                New Delhi, the 27th November, 2008

ORDER

S.O.2767(E)  – In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 and paragraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (National Pharmaceutical Pricing Authority) No. S.O. 1113(E), dated 16th November, 1999, S.O. 1348(E), dated 16th September, 2005, S.O. 186(E), dated 7th February, 2006, S.O. 448(E), dated 29th March, 2006, S.O. 754(E), dated 19th May, 2006, S.O. 1056(E) & 1065(E), dated 11th July, 2006, S.O. 211(E), dated 14th February, 2007, S.O. 1321(E) & 1337(E), dated 1st August, 2007, S.O. 661(E), dated 27th September, 2007, S.O. 2045(E), dated 30th November, 2007 and S.O. 568 (E) & 655(E), dated 24th March, 2008, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the table below as Equivalent MRP inclusive of excise duty and education cess, sales tax/VAT of each of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No. Name of the Formulation Strength Pack Size Ceiling Price (Rs.) Equivalent MRP*(inclusive of all taxes)(Rs.)
(1) (2) (3) (4) (5) (6)

--

Each Each meter dose contains

--

1 Salbutamol +
Beclomethasone Inhaler
Salbutamol – 100 mcg
Beclomethasone Dipropionate-50mcg
200 MT Dose Alumn. Can 98.38 108.31
2 Salbutamol +
Ipratropium Bromide Rotacap
Salbutamol Sulphate eq to
Salbutamol – 100 mcg
Ipratropium Bromide -20mcg
200 MT Dose Alumn. Can 67.28 74.07
3 Salbutamol +
Beclomethasone (CFC) Free Inhaler
Salbutamol Salphate eq to
Salbutamol – 100 mcg
Beclomethasone Dipropionate-50mcg
Suspended in Propeliant HFA-134-a.q.s
Contains Absolute Alcohol 3.75% v/v
200 MT Dose 125.24 137.88

--

Each rotacap contains

--

4 Salbutamol +
Beclomethasone Rotacaps
Salbutamol Sulphate eq to
Salbutamol – 200 mcg
Beclomethasone Dipropionate-100mcg
30’s Bottle 15.16 16.69
5 Salbutamol +
Ipratropium Bromide Rotacap
Salbutamol Sulphate eq to
Salbutamol – 200 mcg
Ipratropium Bromide -40mcg
30’s Bottle 14.68 16.16
6 Levosalbutamol +
Ipratropium Bromide Rotacap
Levosalbutamol – 100mcg
Ipratropium Bromide -40mcg
30’s Bottle 14.52 15.99
7 Salbutamol +
Beclomethasone Rotacap
Salbutamol 200mcg
Beclomethasone Dipropionate-100mcg
10’s Rotacaps 3.80 4.18

--

Each disk tablet contains

--

8 Salbutamol +
Beclomethasone Tablets
Salbutamol Sulphate eq to
Salbutamol – 400 mcg
Beclomethasone Dipropionate-200mcg
8’s Strip/Blister 1.78 1.96
9 Salbutamol +
Beclomethasone Tablets
Salbutamol Sulphate eq to
Salbutamol – 200 mcg
Beclomethasone Dipropionate-100mcg
8’s Strip/Blister 1.26 1.39

--

Each tablet contains

--

10 Salbutamol +
Bromohexine Tablets
Salbutamol Sulphate eq to
Salbutamol- 2mg
Bromohexine – 4mg
10’s Strip/Blister 1.46 1.61
11 Salbutamol +
Ambroxol+
Theophylline Tablets
Salbutamol Sulphate eq to
Salbutamol- 2mg
Ambroxol HCL- 30mg
Theophylline – 100mg
10’s Strip/Blister 1.70 1.87
12 Salbutamol +
Bromohexine+
Etophylline Tablets
Salbutamol Sulphate eq to
Salbutamol- 4mg
Bromohexine – 8mg
Etophylline – 200mg
10’s Strip/Blister 4.20 4.62
13 Salbutamol Tablets Salbutamol – 2 mg 8×250’s Loose Pack 143.12 157.56
14 Salbutamol Tablets Salbutamol – 4 mg 8×250’s Loose Pack 190.62 209.85
15 Salbutamol +
Bromohexine+
Guaiphensin Tablets
Salbutamol – 4 mg
Bromohexene HCL -8mg
Guaiphensin -30mg
10’s Strip/Blister 2.12 2.33

--

Each Sustained Action tablet contains

--

16 Salbutamol Tablets Salbutamol Sulphate eq to
Salbutamol- 4mg
10’s Strip/Blister 2.86 3.15

--

Each capsule contains

--

17 Salbutamol+
Beclomethasone Capsules
Salbutamol Sulphate eq to
Salbutamol- 400mcg
Beclomethasone Dipropionate-200mcg
30’s Bottle 14.76 16.25

--

Each capsule (for inhalation) contains

--

18 Salbutamol+
Beclomethasone Capsules
Salbutamol Sulphate eq to
Salbutamol- 200mcg
Beclomethasone Dipropionate-100mcg
20’s Strip/Blister 8.52 9.38

--

Each disk holder contains

--

19 Salbutamol Disk Salbutamol – 50 mcg
(as Xinafoate)
14 disk x 4’sBlister 1 disk holder 5.80 6.39

--

Each 2.5ml respule/ampoule contains

--

20 Levosalbutamol +
Ipratropium Bromide
Respule/Ampoule
Levosalbutamol – 1.25 mg
Ipratropium Bromide 500mcg
2.5ml Respule/Ampoule 3.74 4.12

*Subject to actual payment of Government levies/taxes, as applicable.

NOTE :

(a)        The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b)        The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c)        Pro-rata pricing for packs of same composition but of different sizes will be applicable vide S.O. No. 83(E) dated 27.1.1998 for tablet and capsule packed in strip/blister.

(d)        For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

(e)        The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing /marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.

(f)        The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

(g)        The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiling price by a factor of 1.1009 as per the existing rates of excise duty and VAT.

(h)        The MRP arrived as above shall be subject to payment of Government levies / taxes as applicable and necessary adjustment in the factor of 1.1009 shall necessarily be required to be made by the manufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes a change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceed the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable as per the factor of 1.1009. The manufacturer/marketing company shall be specifically liable to ensure the compliance of this condition.

(i)        Any other formulation / composition not covered in the above table that has any one of the scheduled drugs in Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respective serial number of the table, as the case may be, unless the manufacturer has got hereafter specific price fixed by the NPPA for that formulation.

(j)        Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the following price order(s) issued prior to this date of notification stand automatically withdrawn :

Sl.No. Price Order No. Date
. -- --

.and any other price order(s) issued earlier for the composition of the formulation pack for which ceiling price is notified in this notification.

PN/105/2008/F

F.No. 8(14)/2008/D.P./NPPA-Div.II

(RAJIV WADHAWAN)
Deputy Director
National Pharmaceutical Pricing Authority

Last Page Updated: 01-06-2019